These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36228400)

  • 1. Alterations in maternal sFlt-1 and PlGF: Time to labor onset in term-/late-term pregnancies with and without placental dysfunction.
    Mitlid-Mork B; Bowe S; Staff AC; Sugulle M
    Pregnancy Hypertens; 2022 Dec; 30():148-153. PubMed ID: 36228400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
    Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL
    Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
    Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
    Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
    Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
    PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble fms-like tyrosine kinase-1 binding or diminished production of placental growth factor?
    Kluivers ACM; Biesbroek A; Visser W; Saleh L; Russcher H; Danser AHJ; Neuman RI
    Ultrasound Obstet Gynecol; 2023 Apr; 61(4):466-473. PubMed ID: 36191149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.
    Park HJ; Kim SH; Jung YW; Shim SS; Kim JY; Cho YK; Farina A; Zanello M; Lee KJ; Cha DH
    BMC Pregnancy Childbirth; 2014 Jan; 14():35. PubMed ID: 24444293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies.
    Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
    Stepan H; Hund M; Andraczek T
    Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
    Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
    Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gestational Age-Specific Reference Ranges for the sFlt-1/PlGF Immunoassay Ratio in Twin Pregnancies.
    De La Calle M; Delgado JL; Verlohren S; Escudero AI; Bartha JL; Campillos JM; Aguarón De La Cruz A; Chantraine F; García Hernández JÁ; Herraiz I; Llurba E; Kurka H; Guo G; Sillman J; Hund M; Perales Marín A
    Fetal Diagn Ther; 2021; 48(4):288-296. PubMed ID: 33784677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction.
    Stepan H; Galindo A; Hund M; Schlembach D; Sillman J; Surbek D; Vatish M
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):168-180. PubMed ID: 35816445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.